NCT00103103终止2 期
A Phase II Combination Trial of PS-341 and 5-FU/LV in Gastric and/or GE Junction Adenocarcinoma
California Cancer Consortium10 个研究点 分布在 1 个国家开始时间: 2005年3月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 试验地点
- 10
- 主要终点
- Response rate as measured by RECIST every 8 weeks
研究概览
简要总结
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fluorouracil and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with fluorouracil and leucovorin may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving bortezomib together with fluorouracil and leucovorin works in treating patients with metastatic or unresectable stomach cancer.
详细描述
OBJECTIVES:
Primary
- Determine response in patients with previously treated metastatic or unresectable gastric or gastroesophageal junction adenocarcinoma treated with bortezomib, fluorouracil, and leucovorin calcium.
Secondary
- Determine time to progression and overall survival of patients treated with this regimen.
- Determine the toxic effects of this regimen in these patients.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Diagnosis of gastric or gastroesophageal junction adenocarcinoma
- •Metastatic or unresectable disease
- •Progressive disease after receiving 1 prior chemotherapy regimen for metastatic disease comprising 1 of the following:
- •Fluorouracil
- •Cisplatin and irinotecan
- •Capecitabine
- •Measurable disease
- •No esophageal cancer
- •No brain metastases
- •PATIENT CHARACTERISTICS:
- •Performance status
- •ECOG 0-2 OR
- •Karnofsky 60-100%
- •Life expectancy
- •At least 3 months
- •Hematopoietic
- •Absolute neutrophil count ≥ 1,500/mm^3
- •Platelet count ≥ 100,000/mm^3
- •Bilirubin normal
- •AST and ALT ≤ 2.5 times upper limit of normal
- •Creatinine ≤ 1.5 mg/dL
- •Cardiovascular
- •No symptomatic congestive heart failure
- •No unstable angina pectoris
- •No cardiac arrhythmia
- •No acute ischemia by EKG
- •No significant conduction abnormality by EKG, including either of the following:
- •Bifasicular block, defined as left anterior hemiblock in the presence of right bundle branch block
- •Second or third degree atrioventricular block
- •No history of cardiac or cerebrovascular disease due to hypotension and tachycardia
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception before, during, and for 6 months after study participation
- •No ongoing or active infection
- •No other uncontrolled illness
- •No peripheral neuropathy ≥ grade 2 within the past 2 weeks
- •No allergy to boron or mannitol
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy
- •More than 4 weeks since prior immunotherapy
- •Chemotherapy
- •More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered
- •Endocrine therapy
- •Not specified
- •Radiotherapy
- •More than 4 weeks since prior radiotherapy and recovered
- •More than 2 weeks since prior major surgery
- •No concurrent highly active anti-retroviral therapy for HIV-positive patients
- •No other concurrent investigational agents
排除标准
- 未提供
结局指标
主要结局
Response rate as measured by RECIST every 8 weeks
次要结局
- Time to progression every 8 weeks
- Overall survival
- Toxicity every 4 weeks
- Molecular correlates on and off study treatment
研究者
研究点 (10)
Loading locations...
相似试验
已完成
1 期
Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal CancerColorectal CancerNCT00280176UNC Lineberger Comprehensive Cancer Center11
已完成
2 期
Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal JunctionEsophageal CancerNCT00107341Alliance for Clinical Trials in Oncology37
已完成
2 期
Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or UreterTransitional Cell Cancer of the Renal Pelvis and UreterBladder CancerNCT00066352University Health Network, Toronto
已完成
2 期
Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell CarcinomaMetastatic Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Bladder CancerRecurrent Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Urethral CancerStage III Bladder CancerStage III Urethral CancerStage IV Bladder CancerStage IV Urethral CancerTransitional Cell Carcinoma of the BladderUreter CancerNCT00072150National Cancer Institute (NCI)40
已完成
2 期
Bortezomib in Treating Patients With Recurrent or Refractory Extensive-Stage Small Cell Lung Cancer Previously Treated With Platinum-Based ChemotherapyLung CancerNCT00068289SWOG Cancer Research Network